Navigation Links
Knee Implant Market Booming in China
Date:1/10/2008

Chinese knee implant market set to skyrocket through 2012, according to

Millennium Research Group

WALTHAM, Mass., Jan. 10 /PRNewswire/ -- According to Millennium Research Group's Chinese Markets for Large-Joint Reconstructive Implants 2008 report, sales of reconstructive knee implants will skyrocket in China, at an almost 25% compound annual growth rate from 2007 through 2012. Strong economic growth, favorable demographics, and an improving quality of life, particularly in the country's urban areas, will drive this market throughout the next five years.

The Chinese reconstructive knee implant market, currently pegged at nearly $100 million, will almost triple to reach just under $300 million by 2012. Because China's strong economic growth has spurred the rise of a middle class, many now have the financial resources to improve their quality of life. Some of the country's aging and osteoporotic citizens are doing so by spending on elective knee implant surgery. In order to accommodate this increasing demand, more surgeons are training to perform knee implant procedures.

"Knee implants are relatively new to China," says Chia Zheng, Analyst at Millennium Research Group. "However, with more people growing aware of treatment options through internet forums and word-of-mouth, and more surgeons becoming trained in implant procedures, this market will boom over the next five years."

The Global Markets for Large-Joint Reconstructive Implants report series covers India, US, Japan, and Europe. Coverage of industry competitors includes Biomet, DePuy, Smith & Nephew, Stryker, Zimmer, local Chinese competitors, and many others.

About Knee Replacement Surgery

Knee replacement surgery is a procedure intended to relieve pain or disability associated with degenerative bone conditions such as osteoarthritis. The surgery consists of replacing the joint surface with a reconstructive implant, which commonly comprise
'/>"/>

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nanowire coating for bone implants, stents
2. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
3. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
4. Implantable device designed to detect, stop seizures under study at MCG
5. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
6. Bone-growing nanomaterial could improve orthopaedic implants
7. RFID Implant Cancer Questions Concern Patients
8. GrantAdler Shipping Novel Implantable Vascular Access Port
9. SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System
10. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
11. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... a one-day event geared to patients and family members, medical professionals, and researchers, ... regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista ... 5, 2015, from 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, ... to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
(Date:8/31/2015)... ... 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been ... Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. ... in both sports in his senior year. He was inducted into the National Honor ...
(Date:8/31/2015)... ... 31, 2015 , ... How can healthcare meet the challenge ... , In a commentary for The American Journal of Managed Care , ... efficacy,” which would bind parties together in agreements to intervene at the earliest ...
Breaking Medicine News(10 mins):Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3
... sick children, study finds , , TUESDAY, Nov. 20 (HealthDay ... at a children,s hospital can cut rates of patient ... care unit, a new study suggests. , "This is ... so that adds to the potential that having rapid ...
... Homecare Month, ARLINGTON, Va., Nov. 20 ... throughout the U.S. will celebrate,Thanksgiving and other holidays ... During November, which is National Homecare Month, the ... medical,equipment and therapies provided in the home offer ...
... and ... Flu Season, ... of,American Scientific Resources (Pink Sheets: ASFX), today announced the,launch of the ... available at Walgreens Stores,nationwide and online at http://www.kidzmed.com . ...
... Precision Optics,Corporation, Inc. (OTC Bulletin Board: POCI), (the "Company") ... first quarter of,fiscal year 2008 ended September 30, 2007. ... revenues for the quarter ended September 30, 2007,were $1,101,728, ... period in,the prior year. This represents the second highest ...
... Marketing Return: What can be measured? ... 2:30 p.m. GMT, WHERE: Pharmaceutical Marketing Society Half-day Conference, 20 Cavendish ... ... of the pharmaceutical analytics company Eularis, will be,delivering a presentation on marketing return ...
... and inexpensive diagnostic tool called MassTag PCR, scientists ... Center for Infection and Immunity implicated a new ... respiratory tract infections in Europe. Their findings are ... Journal of Infectious Diseases (currently available online). , ...
Cached Medicine News:Health News:Rapid Response Teams Can Save Hospitalized Kids 2Health News:Rapid Response Teams Can Save Hospitalized Kids 3Health News:Thanks to Homecare, Millions of Older Americans Celebrate Thanksgiving and Other Holidays at Home 2Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 2Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 3Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 2Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 3Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 4Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 5Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 6Health News:MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP? 2Health News:Recently discovered virus associated with pediatric respiratory tract infection in Germany 2
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: